Loading...
XCSE
ALK B
Market cap4.70bUSD
Apr 03, Last price  
142.40DKK
1D
0.92%
1Q
-11.33%
Jan 2017
209.57%
Name

ALK-Abello A/S

Chart & Performance

D1W1MN
P/E
38.90
P/S
5.73
EPS
3.66
Div Yield, %
—
Shrs. gr., 5y
0.32%
Rev. gr., 5y
11.08%
Revenues
5.54b
+14.78%
1,217,000,0001,489,000,0001,652,000,0001,784,000,0001,935,000,0002,140,000,0002,348,000,0002,345,000,0002,244,000,0002,433,000,0002,569,000,0003,005,000,0002,910,000,0002,915,000,0003,274,000,0003,491,000,0003,916,000,0004,511,000,0004,824,000,0005,537,000,000
Net income
815m
+67.70%
4,302,000,00024,000,000140,000,00095,000,000118,000,000128,000,000200,000,00054,000,00061,000,000181,000,000344,000,000270,000,000-158,000,000-170,000,000-50,000,00025,000,000219,000,000335,000,000486,000,000815,000,000
CFO
1.21b
+81.86%
175,000,00060,000,000362,000,000189,000,000260,000,000274,000,000431,000,00091,000,000146,000,000320,000,000183,000,000405,000,000-387,000,000-95,000,000132,000,000301,000,000468,000,000416,000,000667,000,0001,213,000,000
Dividend
Mar 16, 20175 DKK/sh
Earnings
May 01, 2025

Profile

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
URL
https://www.alk.net/
IPO date
Jan 01, 1961
Employees
2,727
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
5,537,000
14.78%
4,824,000
6.94%
4,511,000
15.19%
Cost of revenue
4,449,000
4,160,000
4,042,000
Unusual Expense (Income)
NOPBT
1,088,000
664,000
469,000
NOPBT Margin
19.65%
13.76%
10.40%
Operating Taxes
242,000
161,000
112,000
Tax Rate
22.24%
24.25%
23.88%
NOPAT
846,000
503,000
357,000
Net income
815,000
67.70%
486,000
45.07%
335,000
52.97%
Dividends
Dividend yield
Proceeds from repurchase of equity
(32,000)
(20,000)
31,000
BB yield
Debt
Debt current
736,000
326,000
267,000
Long-term debt
782,000
740,000
696,000
Deferred revenue
45,000
46,000
49,000
Other long-term liabilities
425,000
476,000
439,000
Net debt
929,000
592,000
742,000
Cash flow
Cash from operating activities
1,213,000
667,000
416,000
CAPEX
(260,000)
(310,000)
(353,000)
Cash from investing activities
(1,417,000)
(375,000)
(351,000)
Cash from financing activities
310,000
(31,000)
(42,000)
FCF
560,000
901,000
(922,000)
Balance
Cash
589,000
474,000
221,000
Long term investments
Excess cash
312,150
232,800
Stockholders' equity
5,308,000
4,465,000
3,988,000
Invested Capital
6,717,850
5,501,200
5,075,000
ROIC
13.85%
9.51%
7.52%
ROCE
15.47%
11.57%
9.23%
EV
Common stock shares outstanding
221,544
221,276
221,373
Price
Market cap
EV
EBITDA
1,360,000
908,000
707,000
EV/EBITDA
Interest
65,000
22,000
24,000
Interest/NOPBT
5.97%
3.31%
5.12%